![Show Menu](styles/mobile-menu.png)
![Page Background](./../common/page-substrates/page0066.png)
66
Scientific Programme /
Thursday, 22 June 2017
WFSBP 2017
THU
004
Gender related differences in reporting side-
effects in Glasgow Antipsychotic Side-effects Scale
for Clozapine (GASS-C scale)
Dragana Ignjatovic Ristic, Serbia and Montenegro
J. Jovic, D. Cohen
005
Pharmacological characterization of receptor-me-
diated Gi / o activation in postmortem human prefrontal
cortical membranes
Yuji Odagaki, Japan
M. Kinoshita, T. Ota, J. J. Meana, L. F. Callado, J. A. Garcia
Sevilla
006
Mania induced by levetiracetam treatment:
A case report
João Fonseca, Portugal
D. Vilaverde, P. Morgado
007
Improvement of social interaction and cognition
by oxytocin for autism-like behaviors in valproic acid-
exposed rats
Kohji Fukunaga, Japan
K. Matsuo, Y. Yabuki
008
Melatonin improved PTSD-like behaviors observed
in FABP3 null mice
Kohji Fukunaga, Japan
Y. Yabuki, Y. Shinoda
009
Memantine activates CaMKII and improves cogni-
tion via KATP channels
Kohji Fukunaga, Japan
S. Moriguchi
010
Modafinil for the treatment of Attention Deficit
Hyperactivity Disorder (ADHD): A meta-analysis
Sheng-Min Wang, Republic of Korea
C.-U. Pae
012
The use of statins for the treatment of depression
in patients with acute coronary syndrome
Sung-Wan Kim, Republic of Korea
J.-M. Kim, I.-S. Shin, H. Kim, Y.-H. Lee, J.-W. Kim, M. Berk,
J.-S. Yoon
013
No cognitive-enhancing effect of GLP-1 receptor
agonism in antipsychotic-treated, obese patients with
schizophrenia
Bjørn Ebdrup, Denmark
P. Ishøy, B. Fagerlund, B. Broberg, N. Bak, F. Knop,
B. Glenthøj
014
Neuro-PGx Card: A new approach to the personal-
ized treatment of CNS disorders
Juan C. Carril, Spain
R. Cacabelos
015
The associations between polymorphisms HTR2A
and development of antipsychotic-induced metabolic
disturbances: Preliminary results of prospective study in
Russian patients
Regina Nasyrova, Russia
S. Dmiriy, T. Vera, I. Dmitriy, S. Kristina, E. Evgeniy,
N. Nicolay
016
Genotyping and phenotyping of CYP2D6 and
CYP3A isoenzymes in patience with alcohol use
disorder
Mikhail Zastrozhin, Russia
017
The impact of a single nucleotide polymorphism in
SIGMAR1 on depressive symptoms in major depressive
disorder and Bipolar Disorder (BP)
Laura Mandelli, Italy
C.-U. Pae, A. Serretti
018
Association of the Leptin Receptor gene (LEPR)
polymorphism with blood pressure in patients with
schizophrenia who are taking clozapine
Shi-Hyun Kang, Republic of Korea
J.-I. Lee
020
Establishment of evidence-based CYP2C19 geno-
type-guided escitalopram dosing recommendations –
a naturalistic study based on 2,088 patients
Marin Jukic, Sweden
E. Molden, M. Ingelman-Sundberg
P-19
POSTER TOUR
13:00–14:30
Congress Hall A 1
Neuropathology & neurophysiology
Chair:
Gregers Wegener, Denmark
001
The effects of intestinal endotoxemia on APP, PS1
and BACE expression in Alzheimer's Disease
Bai Han, People's Republic of China
F. Wu, C. Li, X. Shan, Q. Sun, K. Liu
002
A novel Alzheimer's Disease vaccine: A promising
dual effect for preventing and treating neuropathologi-
cal hallmarks
Iván Carrera, Spain
L. Fernandez Novoa, C. Vigo, R. Cacabelos
004
A case of psychiatric presentation of anti NMDA
receptor encephalitis
Jose Ildefonso Pérez Revuelta, Spain
J. Pascual Juliá, J. M. Pascual Paño, C. Rodríguez Gómez,
J. M. Villagran Moreno